B
CDTX

Bailard’s Cidara Therapeutics CDTX Stock Holding History

Bailard’s Portfolio CDTX Stock Details CDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-1,467
Closed -$113K – 467
2019
Q4 		$113K Buy
+1,467
New +$67.2K 0.01% 525
2016
Q1 		– Sell
-700
Closed -$240K – 269
2015
Q4 		$240K Buy
+700
New +$210K 0.11% 180

Other funds holding CDTX

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
IVM
InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return

Bailard's CDTX Position: Q1 2020 in Review

Bailard sold out of Cidara Therapeutics (CDTX) in Q1 2020, closing a stake of 1,467 shares — an estimated $113K sold.

Bailard first reported a position in CDTX in Q4 2015 and held it in 2 quarters. The position peaked at $240K in Q4 2015. 53 funds tracked by Wall St. Rank hold CDTX as of Q1 2020.

  • Bailard reported no remaining Cidara Therapeutics position as of Q1 2020 after selling out during the quarter.
  • Bailard sold 1,467 Cidara Therapeutics shares in Q1 2020, an estimated $113K.
  • Bailard first reported a position in Cidara Therapeutics in Q4 2015 and held it in 2 quarters.
  • Bailard's Cidara Therapeutics position peaked at $240K in Q4 2015.
  • 53 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q1 2020.

Based on Bailard's 13F filing for Q1 2020, filed 16 Apr 2020.